

**For Immediate Release**

**Net Profit up 45%, Net Revenues up 25%**

**Vadodara July 29<sup>th</sup>, 2016**

Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter ending 30<sup>th</sup> June 2016.

**Financial Highlights**

- Net Sales up 25% to Rs. 736 crores
- Net Profit up 45% to Rs. 102 crores

**Commenting on the results, Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said** "We continue to invest in R&D for future growth. Alembic USA was successfully established and has launched 23 products in the market"

**Operational Highlights for the quarter**

**International Business**

- International formulation business grew by 72% to Rs. 308 crores
- API I & API II successfully audited by the US FDA without any form 483 observations
- 23 products launched by Alembic USA
- 2 ANDA applications were filed, Cumulative ANDA filings at 78
- 1 DMF application was filed, Cumulative DMF filings at 82

**India Branded Formulations**

- India Branded formulations grew 6% to Rs. 278 crore
- Specialty segment grew 16%
  - Cardiology up 16%
  - Anti Diabetic up 31%
  - Gynaecology up 31%

**ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. INDIA • TEL : +91-0265-2280550 • FAX : +91-0265-2282837

Website : [www.alembic-india.com](http://www.alembic-india.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in)

CIN: L24230GJ2010PLC061123

Summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q1 FY17	Q1 FY16	% Change
<b>Formulation</b>			
International	308.51	179.33	72%
India Branded	277.74	262.75	6%
India Generics	21.32	27.80	-23%
<b>API</b>	128.21	119.65	7%
<b>Total</b>	<b>735.78</b>	<b>589.53</b>	<b>25%</b>

The Profit break-up is as under:

(Rs in Crores)

Particulars	Q1 FY17	Q1 FY16	% Change
EBITDA	156.96	104.32	50%
Profit Before Tax	136.90	90.84	51%
Net Profit after Tax	102.02	70.17	45%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by

**ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. INDIA • TEL : +91-0265-2280550 • FAX : +91-0265-2282837

Website : [www.alembic-india.com](http://www.alembic-india.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in)

CIN: L24230GJ2010PLC061123

regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at [www.alembic-india.com](http://www.alembic-india.com);  
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

**For more information contact:**

<b>Ajay Kumar Desai</b>	<b>Mitanshu Shah</b>
Phone: +91 22 – 306 11681	Phone: +91 265 – 3007630
Email: <a href="mailto:ajay.desai@alembic.co.in">ajay.desai@alembic.co.in</a>	Email: <a href="mailto:mitanshu.shah@alembic.co.in">mitanshu.shah@alembic.co.in</a>

**ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. INDIA • TEL : +91-0265-2280550 • FAX : +91-0265-2282837  
Website : [www.alembic-india.com](http://www.alembic-india.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in)

**CIN: L24230GJ2010PLC061123**